Roivant un­veils lat­est spin­out as Pfiz­er en­trusts JAK1/TYK2 to Pri­o­vant

In No­vem­ber, Pfiz­er dis­closed it’s spun out the Phase II dual JAK1/TYK2 in­hibitor to a start­up formed in col­lab­o­ra­tion with an un­named, ex­pe­ri­enced part­ner.

We now know who the part­ner is. And as Pfiz­er and Roivant of­fi­cial­ly take the wraps off Pri­o­vant Ther­a­peu­tics, the com­pa­nies re­veal that they have start­ed two reg­is­tra­tional tri­als of the drug, bre­poc­i­tinib, as part of a broad­er plan to de­vel­op a big, first-in-class fran­chise span­ning mul­ti­ple or­phan and spe­cial­ty au­toim­mune dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER